Targeted delivery of ultra-low doses (picogram range) of a recombinant IFNγ-CNGRC conjugate (IFNγ-NGR) to tumor vasculature overcomes major counter regulatory mechanisms and delays tumor growth in mice [39]. The gene discussed is RTN4R; the disease is neoplasm.